Loading...
XCSE
GMAB
Market cap11bUSD
Apr 02, Last price  
1,275.50DKK
1D
-2.34%
1Q
-16.69%
Jan 2017
8.74%
Name

Genmab A/S

Chart & Performance

D1W1MN
P/E
10.33
P/S
3.77
EPS
123.43
Div Yield, %
—
Shrs. gr., 5y
-36.71%
Rev. gr., 5y
32.03%
Revenues
21.53b
+30.67%
98,505,000135,547,000529,537,000745,113,000586,076,000582,077,000350,936,000484,636,000663,570,000850,385,0001,133,041,0001,816,122,0002,365,436,0003,025,137,0005,366,000,00010,111,000,0008,482,000,00014,595,000,00016,474,000,00021,526,000,000
Net income
7.84b
+80.24%
-393,590,000-438,236,000-383,369,000-965,089,000-1,010,760,000-321,456,000-596,368,000-487,118,000112,362,000301,296,000763,513,0001,187,075,0001,103,551,0001,472,141,0002,166,000,0004,758,000,0002,957,000,0005,452,000,0004,352,000,0007,844,000,000
CFO
7.77b
+5.30%
-208,644,000-379,623,000505,898,000-513,333,000-570,061,000268,171,000-437,225,00070,919,000-127,999,000132,671,000311,449,000327,719,0001,588,972,0001,014,786,0001,326,000,0006,433,000,0002,228,000,0003,912,000,0007,380,000,0007,771,000,000
Earnings
Apr 30, 2025

Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
URL
https://www.genmab.com/
IPO date
Oct 01, 2000
Employees
2,015
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
21,526,000
30.67%
16,474,000
12.87%
14,595,000
72.07%
Cost of revenue
10,733,000
7,856,000
5,562,000
Unusual Expense (Income)
NOPBT
10,793,000
8,618,000
9,033,000
NOPBT Margin
50.14%
52.31%
61.89%
Operating Taxes
1,320,000
1,285,000
1,513,000
Tax Rate
12.23%
14.91%
16.75%
NOPAT
9,473,000
7,333,000
7,520,000
Net income
7,844,000
80.24%
4,352,000
-20.18%
5,452,000
84.38%
Dividends
Dividend yield
Proceeds from repurchase of equity
(3,988,000)
(564,000)
(628,000)
BB yield
4.13%
0.40%
0.03%
Debt
Debt current
92,000
90,000
74,000
Long-term debt
1,966,000
1,450,000
1,120,000
Deferred revenue
480,000
480,000
Other long-term liabilities
30,000
515,000
11,000
Net debt
(19,271,000)
(26,729,000)
(21,263,000)
Cash flow
Cash from operating activities
7,771,000
7,380,000
3,912,000
CAPEX
(304,000)
(376,000)
(317,000)
Cash from investing activities
(9,907,000)
(1,282,000)
(2,761,000)
Cash from financing activities
(3,919,000)
(606,000)
(789,000)
FCF
8,640,000
8,654,000
4,761,000
Balance
Cash
21,101,000
28,135,000
22,324,000
Long term investments
228,000
134,000
133,000
Excess cash
20,252,700
27,445,300
21,727,250
Stockholders' equity
24,107,000
19,149,000
15,132,000
Invested Capital
17,983,300
13,746,000
13,397,000
ROIC
59.71%
54.03%
57.08%
ROCE
26.59%
26.20%
31.66%
EV
Common stock shares outstanding
64,633
65,915
660,096
Price
1,492.50
-30.74%
2,155.00
-26.73%
2,941.00
11.83%
Market cap
96,464,663
-32.09%
142,046,189
-92.68%
1,941,342,454
11.76%
EV
77,193,663
115,317,189
1,920,079,454
EBITDA
11,206,000
8,913,000
9,395,000
EV/EBITDA
6.89
12.94
204.37
Interest
120,000
27,000
21,000
Interest/NOPBT
1.11%
0.31%
0.23%